Compare MBOT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBOT | HCWB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | 35 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.9M | 14.2M |
| IPO Year | 2000 | 2021 |
| Metric | MBOT | HCWB |
|---|---|---|
| Price | $2.03 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.50 | ★ $35.00 |
| AVG Volume (30 Days) | 1.7M | ★ 25.8M |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | $116,887.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | N/A |
| P/E Ratio | ★ N/A | $5.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.25 |
| 52 Week High | $4.62 | $7.83 |
| Indicator | MBOT | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 62.71 |
| Support Level | $2.00 | $1.68 |
| Resistance Level | $2.28 | $3.89 |
| Average True Range (ATR) | 0.15 | 0.60 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 63.56 | 47.15 |
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.